ORD Human Health Toxicity Value for Lithium bis [(trifluoromethyl)sulfonyl]azanide (HQ-115) (CASRN 90076-65-6│DTXSID8044468)
Lithium bis[(trifluoromethyl)sulfonyl]azanide (HQ-115; CASRN 90076-65-6) and its desalted amide form 1,1,1-Trifluoro-N-[(trifluoromethyl)sulfonyl] methanesulfonamide (TFSI) are members of the group of per and polyfluoroalkyl substances (PFAS). This toxicity assessment is a written summary of the potential health effects associated with exposure to HQ-115/TFSI (hazard identification) and identifies the exposure levels (dose-response assessment) at which those health effects may occur. The ORD toxicity assessment focuses on chemical hazard identification and dose-response analyses that can be used along with oral exposure information and other risk management considerations to assess potential risks of HQ-115/TFSI to human health. As part of ORD’s toxicity assessment, the Agency has developed an oral reference dose (RfD) for HQ-115/TFSI. No known studies have evaluated potential cancer effects of HQ-115/TFSI. The focus of the assessment was on noncancer, so no cancer determination was included.